
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
MORG | Derived | EUR | Real-time | |
MORG | Xetra | EUR | Delayed | |
MORd | BATS Europe | EUR | Delayed | |
MOR | NASDAQ | USD | Real-time | |
0NDV | London | EUR | Real-time | |
MORG | TradeGate | EUR | Delayed | |
MORG | Frankfurt | EUR | Delayed | |
MORG | Vienna | EUR | Delayed |
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule to treat myelofibrosis; Felzartamab, an antibody directed against CD38 for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule to promote anti-tumor activity by inhibiting EZH2 and EZH1. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer’s diseases; and Otilimab, an antibody for rheumatoid arthritis. The company has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.
Name | Age | Since | Title |
---|---|---|---|
Marc Cluzel | 66 | 2012 | Independent Chairman of the Supervisory Board |
Michael Brosnan | 66 | 2018 | Independent Member of the Supervisory Board |
Krisja Vermeylen | 59 | 2017 | Independent Member of the Supervisory Board |
George S. Golumbeski | 64 | 2018 | Independent Deputy Chairman of Supervisory Board |
Sharon Curran | 54 | 2019 | Independent Member of Supervisory Board |
Raymond W. Sweet | - | 2016 | Member of Scientific Advisory Board |
Gunther R. Adolf | - | 2016 | Member of Scientific Advisory Board |
Sergio A. Quezada | 46 | 2016 | Member of Scientific Advisory Board |
Bruce D. Cheson | - | 2016 | Member of Scientific Advisory Board |
Andrew Cheng | 56 | 2022 | Independent Member of Supervisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review